Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Besponsa (inotuzumab ozogamicin) is a medication given intravenously (IV) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults.
Fact Table | |
---|---|
Formula | C6516H9996N1732O2022S40 |
License | FDA approved |
Bioavailability | Not applicable (intravenous administration) |
Legal status | Prescription only |
Chemical Name | Inotuzumab Ozogamicin |
Elimination half-life | Approximately 12.3 days |
Dosage (Strength) | 0.9 mg per vial |
Pregnancy | Not recommended; consult a healthcare provider |
Brands | Besponsa |
Protein binding | Not extensively bound |
PubChem CID | 16728488 |
MedlinePlus | a617016 |
ChEBI | 134722 |
ATC code | L01XC26 |
DrugBank | DB12786 |
KEGG | D10848 |
Routes of administration | Intravenous |
Your healthcare provider will decide on a treatment plan that’s appropriate for you. He or she will also decide on Besonspa dosing that is appropriate for you.
A healthcare professional will administer Besponsa IV infusion. If you have any questions or concerns, don’t hesitate to reach out to your healthcare provider.
Inotuzumab ozogamicin is the active ingredient in Besponsa.
Polysorbate 80 (0.36 mg), sodium chloride (2.16 mg), sucrose (180 mg), and tromethamine (8.64 mg) are the inactive ingredients included. Sterile Water for Injection, USP, is used for reconstitution.
According to the most recent Prescribing Information, there are no contraindications to Besponsa.
Besponsa side effects include but are not limited to abnormal blood cell counts, infection, anemia, fatigue, bleeding, fever, nausea, headache, increased liver function tests, abdominal pain, increased gamma-glutamyltransferase, and increased bilirubin levels. Inform your healthcare provider right away of any bothersome or persistent side effects.
Talk to your healthcare provider about Besponsa.
Besponsa. Philadelphia, PA: Wyeth Pharmaceuticals LLC; 2018.